Chronic antiplatelet therapy is not associated with alterations in the presentation, outcome, or host response biomarkers during sepsis: a propensity-matched analysis

Intensive Care Medicine

Volumn 42, Issue 3, 2016, Pages 352-360

  Wiewel, Maryse A ^a   de Stoppelaar, Sacha F ^a   van Vught, Lonneke A ^a   Frencken, Jos F ^b   Hoogendijk, Arie J ^a   Klein Klouwenberg, Peter M C ^b   Horn, Janneke ^a   Bonten, Marc J ^b   Zwinderman, Aeilko H ^a   Cremer, Olaf L ^b   Schultz, Marcus J ^a   van der Poll, Tom ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Antiplatelet; Intensive care unit; Mortality; Sepsis

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CYTOKINE; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; DISEASE SEVERITY; FEMALE; HOSPITAL ADMISSION; HUMAN; IMMUNE RESPONSE; INTENSIVE CARE UNIT; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; NETHERLANDS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; SEPSIS; SHOCK; VASCULAR ENDOTHELIUM; BLOOD;

AGED; ASPIRIN; BIOMARKERS; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; NETHERLANDS; PLATELET AGGREGATION INHIBITORS; PROPENSITY SCORE; PROSPECTIVE STUDIES; SEPSIS;

EID: 84957933274     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-015-4171-9     Document Type: Article

References (34)

1. Adhikari NK, Fowler RA, Bhagwanjee S et al (2010) Critical care and the global burden of critical illness in adults. Lancet 376:1339–1346
2. Angus DC, van der Poll T (2013) Severe sepsis and septic shock. N Engl J Med 369:840–851
3. Timsit JF, Perner A, Bakker J et al (2015) Year in review in Intensive Care Medicine 2014: III. Severe infections, septic shock, healthcare-associated infections, highly resistant bacteria, invasive fungal infections, severe viral infections, Ebola virus disease and paediatrics. Intensive Care Med 41:575–588
4. de Stoppelaar SF, van ‘t Veer C, van der Poll T (2014) The role of platelets in sepsis. Thromb Haemost 112:666–677
5. Schouten M, Wiersinga WJ, Levi M et al (2008) Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol 83:536–545
6. Semple JW, Italiano JE Jr, Freedman J (2011) Platelets and the immune continuum. Nat Rev Immunol 11:264–274
7. Yeaman MR (2010) Platelets in defense against bacterial pathogens. Cell Mol Life Sci 67:525–544
8. Akinosoglou K, Alexopoulos D (2014) Use of antiplatelet agents in sepsis: a glimpse into the future. Thromb Res 133:131–138
9. Tsai MJ, Ou SM, Shih CJ et al (2015) Association of prior antiplatelet agents with mortality in sepsis patients: a nationwide population-based cohort study. Intensive Care Med 41:806–813
10. Klein Klouwenberg PM, Ong DS, Bos LD et al (2013) Interobserver agreement of Centers for Disease Control and Prevention criteria for classifying infections in critically ill patients. Crit Care Med 41:2373–2378
11. Klein Klouwenberg PM, van Mourik MS, Ong DS et al (2014) Electronic implementation of a novel surveillance paradigm for ventilator-associated events. Feasibility and validation. Am J Respir Crit Care Med 189:947–955
12. Dellinger RP, Levy MM, Rhodes A et al (2013) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39:165–228
13. Charlson ME, Pompei P, Ales KL et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383
14. Zimmerman JE, Kramer AA, McNair DS et al (2006) Acute physiology and chronic health evaluation (APACHE) IV: hospital mortality assessment for today’s critically ill patients. Crit Care Med 34:1297–1310
15. Vincent JL, Moreno R, Takala J et al (1996) The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22:707–710
16. Kaukonen KM, Bailey M, Suzuki S et al (2014) Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000–2012. JAMA 311:1308–1316
17. Garner JS, Jarvis WR, Emori TG et al (1988) CDC definitions for nosocomial infections, 1988. Am J Infect Control 16:128–140
18. Calandra T, Cohen J (2005) The international sepsis forum consensus conference on definitions of infection in the intensive care unit. Crit Care Med 33:1538–1548
19. Levy MM, Fink MP, Marshall JC et al (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 31:1250–1256
20. Scicluna BP, Klein Klouwenberg PM, van Vught LA et al (2015) A molecular biomarker to diagnose community-acquired pneumonia on intensive care unit admission. Am J Respir Crit Care Med 192:826–835
21. Klein Klouwenberg PM, Cremer OL, van Vught LA et al (2015) Likelihood of infection in patients with presumed sepsis at the time of intensive care unit admission: a cohort study. Crit Care 19:319
22. Pierrakos C, Vincent JL (2010) Sepsis biomarkers: a review. Crit Care 14:R15
23. Valerio-Rojas JC, Jaffer IJ, Kor DJ et al (2013) Outcomes of severe sepsis and septic shock patients on chronic antiplatelet treatment: a historical cohort study. Crit Care Res Pract 2013:782573
24. Otto GP, Sossdorf M, Boettel J et al (2013) Effects of low-dose acetylsalicylic acid and atherosclerotic vascular diseases on the outcome in patients with severe sepsis or septic shock. Platelets 24:480–485
25. Eisen DP, Reid D, McBryde ES (2012) Acetyl salicylic acid usage and mortality in critically ill patients with the systemic inflammatory response syndrome and sepsis. Crit Care Med 40:1761–1767
26. Sossdorf M, Otto GP, Boettel J et al (2013) Benefit of low-dose aspirin and non-steroidal anti-inflammatory drugs in septic patients. Crit Care 17:402
27. Levi M, de Jonge E, van der Poll T (2006) Plasma and plasma components in the management of disseminated intravascular coagulation. Best Pract Res Clin Haematol 19:127–142
28. Xiang B, Zhang G, Guo L et al (2013) Platelets protect from septic shock by inhibiting macrophage-dependent inflammation via the cyclooxygenase 1 signalling pathway. Nat Commun 4:2657
29. Gudbrandsdottir S, Hasselbalch HC, Nielsen CH (2013) Activated platelets enhance IL-10 secretion and reduce TNF-alpha secretion by monocytes. J Immunol 191:4059–4067
30. Stephen J, Emerson B, Fox KA et al (2013) The uncoupling of monocyte–platelet interactions from the induction of proinflammatory signaling in monocytes. J Immunol 191:5677–5683
31. Antonino MJ, Mahla E, Bliden KP et al (2009) Effect of long-term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting. Am J Cardiol 103:1546–1550
32. Al-Bahrani A, Taha S, Shaath H et al (2007) TNF-α and IL-8 in acute stroke and the modulation of these cytokines by antiplatelet agents. Curr Neurovasc Res 4:31–37
33. Lauhio A, Hastbacka J, Pettila V et al (2011) Serum MMP-8, -9 and TIMP-1 in sepsis: high serum levels of MMP-8 and TIMP-1 are associated with fatal outcome in a multicentre, prospective cohort study. Hypothetical impact of tetracyclines. Pharmacol Res 64:590–594
34. Vanlaere I, Libert C (2009) Matrix metalloproteinases as drug targets in infections caused by gram-negative bacteria and in septic shock. Clin Microbiol Rev 22:224–239